V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220018046 | 220009337 | 1.9 | 68 | Curative (C) | 2016-08-08 | 2016-09-24 | EOX | N | N | 220035292 | BUSULFAN + FLUDARABINE + METHOTREXATE |
| 220018047 | 220014955 | 1.5 | 51.3 | Palliative (P) | null | 2014-01-28 | ALL UKALL2011 Maintenance B1 | null | N | 220035295 | IPILIMUMAB |
| 220018048 | 220009339 | 1.79 | 99.4 | Palliative (P) | 2014-02-08 | 2014-07-26 | DOXORUBICIN | N | N | 220035299 | FCR |
| 220018049 | 220014956 | null | null | Curative (C) | 2015-08-02 | 2015-08-20 | LENALIDOMIDE | N | null | 220035304 | CYTARABINE + FLUDARABINE |
| 220018050 | 220014956 | 1.65 | null | Curative (C) | 2015-01-17 | 2015-01-17 | Cisplatin + Radiotherapy | N | N | 220035304 | DOXORUBICIN |
| 220018051 | 220021920 | 1.68 | 72.6 | Curative (C) | 2019-01-07 | 2019-01-07 | CYTARABINE + FLUDARABINE | 2 | null | 220035316 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220018052 | 220022310 | 1.63 | 84.9 | Palliative (P) | 2013-04-18 | 2013-04-25 | ATG + BUSULFAN + CYCLOPHOSPHAMIDE | N | N | 220035320 | ARSENIC TRIOXIDE + ATRA |
| 220018053 | 220009342 | 1.4 | 62 | Palliative (P) | 2015-08-18 | 2015-08-18 | Ipilimumab | 2 | N | 220035326 | BUSULPHAN |
| 220018054 | 220009344 | 1.61 | 80.5 | Palliative (P) | 2018-03-20 | 2018-03-20 | Ipilimumab | N | N | 220035327 | LENALIDOMIDE |
| 220018055 | 220009345 | 1.69 | null | Adjuvant (A) | 2015-01-13 | 2015-02-18 | Trifluridine + Tipiracil | N | N | 220035329 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN |
| 220018056 | 220014960 | 1.73 | 78.4 | Not known (9) | 2013-08-21 | 2013-08-21 | ATG + Busulfan + Fludarabine + Thiotepa | 2 | N | 220035332 | VIDE |
| 220018057 | 220014962 | 1.77 | 77.3 | Curative (C) | 2015-05-16 | 2015-05-28 | PEMBROLIZUMAB | N | N | 220035338 | CARBOPLATIN |
| 220018058 | 220014963 | null | 73.8 | Disease modification (D) | 2013-02-15 | 2013-04-03 | LENALIDOMIDE | N | null | 220035347 | CYTARABINE IT + METHOTREXATE |
| 220018061 | 220009358 | 1.49 | 58.9 | Disease modification (D) | 2014-11-15 | 2015-02-15 | CYTARABINE + MITOXANTRONE | N | N | 220035373 | VINORELBINE |
| 220018062 | 220009362 | 1.64 | 67.6 | Palliative (P) | 2017-06-03 | 2017-08-23 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE | 2 | null | 220035392 | VIDE |
| 220018063 | 220009365 | null | 57.1 | Curative (C) | 2013-08-29 | 2013-08-29 | CLOFARABINE + CYCLO + CYTARABINE + ETOP | N | N | 220035399 | GDCVP |
| 220018064 | 220009366 | null | 51 | Curative (C) | 2016-01-21 | 2016-01-22 | BUSULFAN + CYCLO | null | N | 220035401 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018065 | 220014971 | 1.63 | 87.2 | Curative (C) | 2016-09-14 | 2016-10-31 | Capecitabine | 02 | N | 220035406 | MACE |
| 220018066 | 220009370 | null | null | Curative (C) | 2016-01-24 | 2016-01-31 | MITOXANTRONE + TRETINOIN | N | null | 220035412 | MELPHALAN |
| 220018067 | 220009377 | null | null | Palliative (P) | 2013-12-17 | 2013-12-25 | MACE | null | null | 220035414 | BUSULFAN + FLUDARABINE |
| 220018068 | 220014974 | 1.83 | 108.5 | null | 2015-12-19 | 2015-12-19 | CYTARABINE + MITOXANTRONE | N | N | 220035417 | FIGARO TRIAL |
| 220018069 | 220009380 | null | 103.4 | Curative (C) | 2018-03-09 | 2018-04-08 | Depocyte Intrathecal | null | null | 220035428 | ARSENIC TRIOXIDE + ATRA |
| 220018071 | 220014976 | 1.75 | null | Neo-adjuvant (N) | 2018-02-09 | 2018-03-23 | ALL UKALL60+ TRIAL | N | N | 220035451 | MITOXANTRONE + TRETINOIN |
| 220018072 | 220009387 | null | 90.5 | Disease modification (D) | 2017-08-12 | 2017-08-12 | FLUDARABINE | N | N | 220035454 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018074 | 220021922 | null | null | Palliative (P) | 2014-06-13 | 2014-06-20 | R IVAC | N | Y | 220035488 | SPANISH MAINTENANCE |
| 220018075 | 220009395 | null | null | Curative (C) | 2017-07-19 | 2017-08-23 | Methotrexate High Dose (3g/m2) | Y | N | 220035492 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018076 | 220009396 | 1.76 | 78.6 | Curative (C) | 2013-08-13 | 2013-12-11 | ALL UKALL2011 Std BFM Cons B | null | N | 220035497 | ARSENIC TRIOXIDE + ATRA |
| 220018077 | 220018178 | null | 76.6 | null | 2013-06-06 | 2013-06-09 | MERCAPTOPURINE + METHOTREXATE | 2 | N | 220035508 | EOX |
| 220018078 | 220009400 | null | 104.9 | Not known (9) | 2016-10-15 | 2016-10-15 | CAP | 2 | N | 220035535 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 220018082 | 220009409 | 1.49 | 58 | Curative (C) | 2014-12-03 | 2015-01-03 | CYTARABINE + MITOXANTRONE | N | N | 220035549 | FIGARO TRIAL |
| 220018083 | 220014993 | 1.84 | null | null | 2016-12-05 | 2016-12-14 | INTERFERON | N | N | 220035566 | INTERFERON |
| 220018085 | 220009417 | 1.68 | 75.1 | Curative (C) | 2018-03-05 | 2018-03-26 | INTERFERON | 2 | N | 220035600 | ETOPOSIDE |
| 220018086 | 220009419 | 1.51 | 55.2 | Disease modification (D) | 2015-02-19 | 2015-02-19 | DABRAFENIB + TRAMETINIB | Y | N | 220035603 | CARBOPLATIN |
| 220018087 | 220009422 | 1.67 | 79.2 | Not known (9) | 2015-03-18 | 2015-03-30 | BUSULFAN + CYCLO | N | N | 220035628 | PEMBROLIZUMAB |
| 220018088 | 220009422 | 1.75 | 69.1 | Disease modification (D) | 2014-08-28 | 2014-08-29 | BUSULFAN + CYCLO | Y | N | 220035628 | BUSULPHAN + CYCLO |
| 220018089 | 220009427 | 1.8 | 0 | Curative (C) | 2017-01-15 | 2017-01-27 | MITOXANTRONE + TRETINOIN | null | N | 220035638 | UKALL 60+ TRIAL |
| 220018090 | 220009427 | null | 39.2 | Curative (C) | 2016-07-05 | 2016-07-06 | Bevacizumab+Carbo+Pacliaxel | N | N | 220035638 | NHL 2003 |
| 220018091 | 220009431 | 1.56 | 118.3 | Curative (C) | 2015-05-03 | 2015-05-29 | Erlotinib | 02 | N | 220035672 | CARBOPLATIN + VINORELBINE |
| 220018092 | 220018189 | 1.9 | 84 | Curative (C) | 2013-12-09 | 2013-12-09 | Busulfan + Cyclophos Conditioning | N | N | 220035685 | CETUXIMAB + IRINOTECAN + MDG |
| 220018093 | 220018189 | null | null | Curative (C) | 2018-02-01 | 2018-02-07 | Methotrexate High Dose (3g/m2) | null | null | 220035685 | MITOXANTRONE + TRETINOIN |
| 220018094 | 220009437 | null | 79.3 | Curative (C) | 2018-01-21 | 2018-01-21 | CISPLATIN + ETOPOSIDE | N | N | 220035738 | VIOLA TRIAL |
| 220018095 | 220009438 | null | 71.6 | Curative (C) | 2017-07-26 | 2017-07-26 | CHLVPP | N | N | 220035738 | FLUDARABINE |
| 220018097 | 220015008 | null | 87.1 | Curative (C) | 2018-03-11 | 2018-03-11 | CAMELLIA Trial | 2 | N | 220035765 | CETUXIMAB |
| 220018098 | 220009446 | null | null | Not known (9) | 2017-03-04 | 2017-03-21 | AFATINIB | N | null | 220035768 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 220018100 | 220009450 | 0 | 87.1 | Disease modification (D) | 2016-01-07 | 2016-10-07 | ALL UKALL60+ TRIAL | 02 | N | 220035793 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018101 | 220009452 | 1.6 | 108 | null | 2014-03-20 | 2014-05-12 | ALL UKALL2011 Std BFM Cons B | 02 | N | 220035797 | ARSENIC TRIOXIDE + ATRA |
| 220018102 | 220018194 | 1.6 | 94 | Disease modification (D) | 2018-05-30 | 2018-09-14 | Cetuximab+Cisplatin+FU (> Cycle 2) | 2 | null | 220035808 | CYTARABINE + MITOXANTRONE |
| 220018103 | 220021599 | 1.69 | 81.3 | null | 2014-01-06 | 2014-01-18 | Epirubicin | N | null | 220035815 | FLUDARABINE |
| 220018104 | 220009454 | null | null | Curative (C) | 2016-02-06 | 2016-02-06 | Methotrexate High Dose (3g/m2) | 02 | N | 220035840 | EOX |
| 220018105 | 220009455 | 1.68 | 47.6 | Palliative (P) | 2013-10-31 | 2013-10-31 | PEMBROLIZUMAB | N | N | 220035846 | FLUOROURACIL |